At Novo Nordisk, when conducting clinical trials, our priorities are
patient safety and clinical trial integrity. We are continuing all of
our already-initiated clinical trials and we do not expect significant
delays in those that are close to finalisation.
In the current situation, we are in close dialogue with trial
investigators across the globe and we rely on their judgment to pause
any ongoing trial recruitment and minimise patient visits to sites in
order to coincide with regular medical care visits.
We also observe that trial follow-up is increasingly difficult, and
we are working with relevant trial sites, investigators and
authorities to find the best solutions in the situation. To reflect
the current strain on the healthcare system, no new trials will be initiated.